Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel in Relapsed/Refractory CNS Lymphoma
NCT04608487Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2020
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axicabtagene ciloleucel in Central Nervous System Lymphoma (CNSL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 at 24 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
Central Nervous System Lymphoma (CNSL)
Beyond the preview
Go deeper on NCT04608487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608487.